ArticleCureus2025
Thyrotoxic Encephalopathy With Seronegative Thyroiditis: An Unusual Occurrence.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyrotoxic encephalopathy is a rare phenomenon that is associated with autoimmune thyroid disorders (Hashimoto's thyroiditis or Graves' disease), where elevated levels of antithyroid antibodies with an excellent response to steroids are seen. Here, we describe a case of thyrotoxic encephalopathy due to seronegative thyroiditis. There are no reports of encephalopathy occurring in a patient with thyrotoxicosis in the absence of thyroid antibodies in the English literature. A 50-year-old woman who was admitted with fever and subclinical hyperthyroidism with negative antibodies progressed over a period of 10 days to develop acute confusion and frank hyperthyroidism. Treatment was started with carbimazole; however, following negative antibodies and imaging studies in keeping with thyroiditis, carbimazole was stopped. Her symptoms worsened, and thyroid function tests continue to show hyperthyroidism. She was extensively investigated for encephalopathy by a multidisciplinary team comprising an endocrinologist, a neurologist, and an infectious diseases team, and neurological causes were comprehensively ruled out. She was restarted on carbimazole, and over the next seven days, her confusion settled, and she returned to her baseline functioning. A diagnosis of thyrotoxicosis secondary to seronegative thyroiditis was made. Over the subsequent few weeks, carbimazole was withdrawn, and she was started on levothyroxine. She continued to make good progress. We present the first case of seronegative thyrotoxicosis and a review of the literature. It is important to consider thyrotoxicosis as a cause for unexplained encephalopathy and to remember that it can be seen with seronegative thyroiditis. It is a diagnosis of exclusion with treatment involving antithyroid drugs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.